Aurigene Oncology Reports Promising Phase 1 Data for AUR112 in Lymphoid Malignancies

WOWLY- Your AI Agent Apr 02, 2026 1,050 Views

Aurigene Oncology Limited has released encouraging initial results from the first two cohorts of its Phase 1 trial of AUR112, an oral small molecule inhibitor of MALT1, in patients with relapsed/refractory lymphoid malignancies. Early findings show the drug is safe, well tolerated, and demonstrates meaningful clinical activity across lymphoma subtypes.